Giving people the power to personalize their health

The Digital Health Leader

for Genomic Medicine

$60 million Series C financing and a strategic acquisition

Today, we are proud to announce that we have raised $60 million in a Series C financing — just more than a year after our Series B close. In addition, we have acquired GeneMatters, a leading telehealth genetic counseling and software solutions company, and we welcome their team to the Genome Medical family.

We are merging two remarkable teams of industry innovators and clinical experts — who all share a vision of personalizing health care for everyone through on-demand access to genetic health services and genomic care. And in doing so, we are creating the clear digital health leader for genomic medicine.

Why we are so excited

Rapid & Strategic
Expansion

We are growing companies, and that won’t change — it will just accelerate. Our combined forces and resources will enable us to expand our teams, speed up technology development, foster innovation, and serve the needs of more patients and providers.

The Best in Virtual
Genomics Care

We are bringing together two powerful teams of industry innovators and clinical experts. We now have a team of more than 100 specialists — medical geneticists, genetic counselors, primary care physicians, pharmacists and other specialists. In depth and scale, we offer the medical care of the future — today. We are your genomic specialists for life.

Powerful Investor
Support

Our Series C was led by Casdin Capital, with participation from leading life sciences investors such as Perceptive Advisors, Amgen Ventures and GV (formerly Google Ventures). The support of these visionary investors is an acknowledgement that together, Genome Medical and GeneMatters will lead the way in rapidly opening up the genomics revolution through genetic health services and genomic care.

The addition of GeneMatters, along with our Series C financing, propels us into the next phase of commercial growth and enables us to realize the genome-driven personalization of health.

LISA ALDERSONCO-FOUNDER AND CEO OF GENOME MEDICAL

Joining the Genome Medical family allows for expanded capabilities, broader reach and ultimately more patients and providers being served. We are thrilled to be joining forces with this talented team that shares our mission, vision and passion for patient care.

JILL DAVIESCO-FOUNDER AND PRESIDENT OF GENEMATTERS

Additional Insights from Genome Medical

Telemedicine: The “New Normal” for Genomic Services

In the years-long integration of telehealth into the health care system, 2020 will definitely be recognized as a tipping point. Starting in the second quarter, millions of people participated for the first time in virtual visits with their health care providers. While the impetus was the COVID-19 pandemic, indications are that many patients appreciate the convenience and safety that virtual care offers.

Reflecting on the first five, looking ahead to the next five and beyond

Five years on, we have stayed true to our mission — meaning, as we envisaged, it is Genome Medical’s unique, combined application of virtual care, digital health and genetic expertise that is the market-leading solution to the gap we identified. We are providing genomic insights as a service to harness the power of personalized medicine.

A Q&A between Samsung’s Young Sohn & Genome Medical’s Lisa Alderson

Young Sohn, Chairman of the Board, HARMAN and Senior Advisor, Samsung Electronics, talks to our CEO and Co-founder Lisa Alderson about her plans to make genomics more accessible for everyone, the ethical questions raised by genomics and the critical role this technology played in developing COVID vaccines in record time.

Partner Support

Provide standard-of-care genetics to more patients through virtual, on-demand specialty care.

LEARN MORE

Individual Service

Interested in exploring your DNA? Our genetic experts can help you make the right decisions.

START NOW